Summary of Study ST003522
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR002137. The data can be accessed directly via it's Project DOI: 10.21228/M8CZ33 This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
Download mwTab file (text) | Download mwTab file(JSON)
| Study ID | ST003522 |
| Study Title | Untargeted mass spectrometry analysis of neutral lipids in MC38 tumors and visceral adipose tissues of control-diet and high fat diet-fed C57BL/6 mice |
| Study Summary | Both tumors and the visceral adipose tissues were collected from Control Diet (CD) and High Fat Diet (HFD)-fed C57BL/6 (B6) mice. Mice were fed a HFD for 2 months. For tumor studies, MC38 tumors were subcutaneously injected after 2 months of feeding mice the HFD. Tumors were allowed to grow for 3 weeks, at which point, tumors from CD and HFD-fed mice were harvested and snap frozen. Visceral adipose tissues were also collected from these mice and snap frozen. Subsequently, samples were sent to the UC Davis Metabolomics Core for analysis of neutral lipids. Some triglycerides, including TG(54:3), were found to be significantly more abundant in the adipose tissue and tumors of HFD-fed mice compared to CD-fed mice. |
| Institute | Stanford University |
| Last Name | Engleman |
| First Name | Edgar |
| Address | 3373 Hillview Avenue |
| sbagchi@stanford.edu | |
| Phone | 4086214773 |
| Submit Date | 2024-09-24 |
| Analysis Type Detail | LC-MS |
| Release Date | 2024-12-02 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
| Project ID: | PR002137 |
| Project DOI: | doi: 10.21228/M8CZ33 |
| Project Title: | Acid-sensing receptor, GPR65, on tumor macrophages drives accelerated tumor growth in obesity |
| Project Summary: | Multiple cancers, including colorectal cancer (CRC), are more frequent and often more aggressive in obese individuals. Here, we show that macrophages accumulate within tumors of obese CRC patients and in obese CRC mice and promote accelerated tumor growth. These changes are initiated by oleic acid accumulation and subsequent tumor cell-derived acid production, and driven by signaling through GPR65, an acid-sensing receptor on CRC-associated macrophages. We demonstrate a similar role for GPR65 in hepatocellular carcinoma (HCC) in obese mice. Tumors in obese patients with CRC or HCC also exhibit increased GPR65 expression, suggesting that the mechanism revealed here likely contributes to tumor growth in a range of obesity-associated cancers and represents a potential therapeutic target. |
| Institute: | Stanford University |
| Last Name: | Bagchi |
| First Name: | Sreya |
| Address: | 3373 Hillview Avenue |
| Email: | sbagchi@stanford.edu |
| Phone: | 4086214773 |
Subject:
| Subject ID: | SU003651 |
| Subject Type: | Mammal |
| Subject Species: | Mus musculus |
| Taxonomy ID: | 10090 |
| Species Group: | Mammals |
Factors:
Subject type: Mammal; Subject species: Mus musculus (Factor headings shown in green)
| mb_sample_id | local_sample_id | Diet | Sample source |
|---|---|---|---|
| SA386784 | CD5 | CD | MC38 murine colorectal tumor |
| SA386785 | CD2 | CD | MC38 murine colorectal tumor |
| SA386786 | CD1 | CD | MC38 murine colorectal tumor |
| SA386787 | CD4 | CD | MC38 murine colorectal tumor |
| SA386788 | CD3 | CD | MC38 murine colorectal tumor |
| SA386789 | CD10 | CD | Visceral adipose tissue |
| SA386790 | CD9 | CD | Visceral adipose tissue |
| SA386791 | CD7 | CD | Visceral adipose tissue |
| SA386792 | CD8 | CD | Visceral adipose tissue |
| SA386793 | CD6 | CD | Visceral adipose tissue |
| SA386794 | HFD5 | HFD | MC38 murine colorectal tumor |
| SA386795 | HFD4 | HFD | MC38 murine colorectal tumor |
| SA386796 | HFD1 | HFD | MC38 murine colorectal tumor |
| SA386797 | HFD3 | HFD | MC38 murine colorectal tumor |
| SA386798 | HFD2 | HFD | MC38 murine colorectal tumor |
| SA386799 | HFD6 | HFD | Visceral adipose tissue |
| SA386800 | HFD7 | HFD | Visceral adipose tissue |
| SA386801 | HFD8 | HFD | Visceral adipose tissue |
| SA386802 | HFD9 | HFD | Visceral adipose tissue |
| SA386803 | HFD10 | HFD | Visceral adipose tissue |
| Showing results 1 to 20 of 20 |
Collection:
| Collection ID: | CO003644 |
| Collection Summary: | MC38 tumors and visceral adipose tissues from CD and HFD-fed mice were collected 3 weeks post tumor implantation. MC38 tumors were subcutaneously injected after 2 months of feeding mice the HFD. Tumors were allowed to grow for 3 weeks, at which point, tumors from CD and HFD-fed mice were harvested and snap frozen. Visceral adipose tissues were also collected from these mice and snap frozen. |
| Sample Type: | Whole tumor, Visceral adipose tissue |
Treatment:
| Treatment ID: | TR003660 |
| Treatment Summary: | Mice were fed either CD or HFD for two months. |
Sample Preparation:
| Sampleprep ID: | SP003658 |
| Sampleprep Summary: | Both tumors and visceral adipose tissues were isolated from the mice and immediately snap frozen in liquid nitrogen. Subsequently, they were sent for analysis to the UC Davis Metabolomics Core. |
| Sampleprep Protocol Filename: | Fiehn_laboratory_Lipidomics_Protocol.pdf |
Combined analysis:
| Analysis ID | AN005784 |
|---|---|
| Analysis type | MS |
| Chromatography type | Reversed phase |
| Chromatography system | Agilent 1290 Infinity |
| Column | Waters ACQUITY UPLC CSH C18 (100 x 2.1mm,1.7um) |
| MS Type | ESI |
| MS instrument type | QTOF |
| MS instrument name | Agilent 6530 QTOF |
| Ion Mode | POSITIVE |
| Units | Relative peak intensity |
Chromatography:
| Chromatography ID: | CH004390 |
| Methods Filename: | Fiehn_laboratory_Lipidomics_Protocol.pdf |
| Instrument Name: | Agilent 1290 Infinity |
| Column Name: | Waters ACQUITY UPLC CSH C18 (100 x 2.1mm,1.7um) |
| Column Temperature: | 65°C |
| Flow Gradient: | 0 min 15% (B), 0–2 min 30% (B), 2–2.5 min 48% (B), 2.5–11 min 82% (B), 11–11.5 min 99% (B), 11.5–12 min 99% (B), 12–12.1 min 15% (B), 12.1–15 min 15% (B) |
| Flow Rate: | 0.6 mL/min |
| Solvent A: | 60% acetonitrile/40% water; 10 mM ammonium formate; 0.1% formic acid |
| Solvent B: | 90% isopropanol/10% acetonitrile; 10 mM ammonium formate; 0.1% formic acid |
| Chromatography Type: | Reversed phase |
MS:
| MS ID: | MS005504 |
| Analysis ID: | AN005784 |
| Instrument Name: | Agilent 6530 QTOF |
| Instrument Type: | QTOF |
| MS Type: | ESI |
| MS Comments: | The samples were loaded up on an Agilent 1290 Infinity LC stack. The positive mode was run on an Agilent 6530 with a scan range of m/z 120-1200 Da with an acquisition speed of 2 spectra/s. Positive mode has between 0.5 and 2 uL injected onto a Waters ACQUITY UPLC CSH C18 1.7um 2.1x100mm Column with VanGuard PreColumn 2.1x5 mm . The gradient used is 0 min 15% (B), 0–2 min 30% (B), 2–2.5 min 48% (B), 2.5–11 min 82% (B), 11–11.5 min 99% (B), 11.5–12 min 99% (B), 12–12.1 min 15% (B), 12.1–15 min 15% (B) with a flow rate of 0.6 mL/min. The other sample aliquot was run in negative mode, which was run on Agilent 1290 Infinity LC stack, and injected on the same column, with the same gradient. and using an Agilent 6550 QTOF mass spec. The acquisition rate was 2 spectra/s with a scan range of m/z 60-1200 Da. The mass resolution for the Agilent 6530 is 10,000 for ESI (+) and 30,000 for ESI (-) for the Agilent 6546. |
| Ion Mode: | POSITIVE |
| Analysis Protocol File: | Fiehn_laboratory_Lipidomics_Protocol.pdf |
